Tildrakizumab efficacy and safety in patients with psoriasis and concomitant metabolic syndrome: post hoc analysis of 5‐year data from reSURFACE 1 and reSURFACE 2

BACKGROUND: Limited data are available on long‐term efficacy and safety of biologics in patients with psoriasis and metabolic syndrome (MetS), a common comorbidity. OBJECTIVES: This analysis updates tildrakizumab efficacy and safety for up to 5 years in patients with and without MetS. METHODS: This...

Descripción completa

Detalles Bibliográficos
Autores principales: Fernandez, A.P., Dauden, E., Gerdes, S., Lebwohl, M.G., Menter, M.A., Leonardi, C.L., Gooderham, M., Gebauer, K., Tada, Y., Lacour, J.P., Bianchi, L., Egeberg, A., Pau‐Charles, I., Mendelsohn, A.M., Rozzo, S.J., Mehta, N.N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles and Short Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9545614/
https://www.ncbi.nlm.nih.gov/pubmed/35460287
http://dx.doi.org/10.1111/jdv.18167

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9545614/
https://www.ncbi.nlm.nih.gov/pubmed/35460287
http://dx.doi.org/10.1111/jdv.18167

Ejemplares similares